Lingvay I, Sumithran P, Cohen RV, le Roux CW (2022) Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation
At TrimRx, we are dedicated to empowering you on this journey
The four components span distinct structural classes and non-overlapping pathway layers: BPC-157 for angiogenic and growth-factor signaling, GHK-Cu for copper-mediated extracellular-matrix and collagen biology, TB-500 (Thymosin Beta-4) for actin-driven cell migration, and KPV (the C-terminal -MSH fragment) for NF-B and inflammatory-cytokine modulation
Safe & reliable Developed to perfectly complement GLP-1 medications
Special considerations for different GLP-1 delivery methods Not all GLP-1 medications come as traditional injections, and the delivery method affects site selection considerations
The 2022 ASMBS/IFSO guidelines recommend consideration for patients with BMI 35 kg/m regardless of comorbidities, and for those with BMI 30-34.9 kg/m with metabolic disease